Synlogic (SYBX) AI Stock Analysis

• Market Cap: $14.94M
• Dividend Yield: N/A
• Average Volume (3M): 41.08K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.73
• Revenue Growth: N/A
• EPS Growth: 46.81%
• Country: US
• Employees: 1
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 12,248,950
• 10 Day Avg. Volume: 24,108
• 30 Day Avg. Volume: 41,078
• PEG Ratio: 0.15
• Price to Book (P/B): 1.16
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -3.16
• Enterprise Value/Market Cap: <0.01
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: >-0.01
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 53 Neutral
• Price Target: $1.00 ▼(-17.36% Downside)
• Action: Reiterated
• Date: 08/18/26

Positive Factors

Debt-Free Balance Sheet

Eliminating debt reduces interest and refinancing pressure, giving Synlogic greater financial flexibility while it develops therapies. Positive equity provides some cushion, although the company remains dependent on funding because it has not reached profitability.

Negative Factors

No Commercial Revenue

The lack of recurring revenue shows that Synlogic has not yet commercialized its platform and has limited operating leverage. Future value therefore depends heavily on clinical success, regulatory progress, and eventual product adoption rather than an established revenue base.

Synlogic Business Overview & Revenue Model

Company Description

Synlogic, Inc. does not have significant operations. It was previously engaged in the discovery and development of synthetic biotics to treat metabolic diseases. Synlogic, Inc. is based in Winchester, Massachusetts....

How the Company Makes Money

null...

Synlogic Financial Statement Overview

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	8.00K	3.37M	1.18M	1.75M
Gross Profit	0.00	0.00	8.00K	3.37M	1.18M	1.75M
EBITDA	-3.71M	-3.53M	-22.06M	-55.31M	-63.63M	-58.12M
Net Income	-655.00K	-1.00M	-23.36M	-57.28M	-66.15M	-60.56M
Balance Sheet
Total Assets	13.48M	15.45M	19.83M	75.55M	110.86M	174.74M
Cash, Cash Equivalents and Short-Term Investments	13.18M	14.67M	18.86M	47.75M	77.63M	128.59M
Total Debt	0.00	0.00	0.00	17.27M	20.30M	20.59M
Total Liabilities	1.46M	3.58M	7.08M	32.90M	28.25M	27.47M
Stockholders Equity	12.02M	11.86M	12.75M	42.66M	82.61M	147.27M
Cash Flow
Free Cash Flow	-3.84M	-4.36M	-31.67M	-51.83M	-57.62M	-52.88M
Operating Cash Flow	-3.84M	-4.36M	-31.66M	-51.61M	-56.89M	-52.20M
Investing Cash Flow	0.00	167.00K	25.34M	38.77M	58.35M	-53.25M
Financing Cash Flow	0.00	0.00	172.00K	20.94M	-2.04M	89.38M

Synlogic Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.21
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SYBX, the sentiment is Positive. The current price of 1.21 is above the 20-day moving average (MA) of 1.20, above the 50-day MA of 0.91, and above the 200-day MA of 0.86, indicating a bullish trend. The MACD of 0.09 indicates Positive momentum. The RSI at 67.38 is Neutral, neither overbought nor oversold. The STOCH value of 59.26 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SYBX.

Synlogic Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SYBX	53 Neutral	$14.94M	-21.79	-5.42%	―	―	46.81%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CING	46 Neutral	$78.53M	-1.09	-238.41%	―	―	37.29%
ALLR	46 Neutral	$21.32M	-1.77	-109.94%	―	―	91.38%
ICU	45 Neutral	$13.75M	-0.79	-146.29%	―	123.63%	83.96%
APVO	42 Neutral	$4.34M	-0.01	-198.50%	―	―	99.41%
LSTA	40 Underperform	$16.31M	-1.11	-101.90%	―	-90.65%	26.48%

Synlogic Corporate Events